1. Home
  2. SBR vs ANL Comparison

SBR vs ANL Comparison

Compare SBR & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sabine Royalty Trust

SBR

Sabine Royalty Trust

HOLD

Current Price

$73.27

Market Cap

1.1B

Sector

Energy

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$15.67

Market Cap

998.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBR
ANL
Founded
1982
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
998.8M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
SBR
ANL
Price
$73.27
$15.67
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$20.00
AVG Volume (30 Days)
21.8K
158.5K
Earning Date
05-14-2026
04-10-2026
Dividend Yield
6.41%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$36.02
Revenue Next Year
N/A
N/A
P/E Ratio
$12.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$65.31
$0.88
52 Week High
$84.39
$17.25

Technical Indicators

Market Signals
Indicator
SBR
ANL
Relative Strength Index (RSI) 46.40 61.75
Support Level $72.58 $12.45
Resistance Level $76.59 $17.25
Average True Range (ATR) 1.39 1.08
MACD -0.22 0.04
Stochastic Oscillator 18.18 86.29

Price Performance

Historical Comparison
SBR
ANL

About SBR Sabine Royalty Trust

Sabine Royalty Trust formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: